Application Number	10/066,782	F	Applicant(s)/Patent under Reexamination GRIFFITHS ET AL.	
Document Code - DISQ	Internal Doc		cument – DO NOT MAIL	
	7			
TERMINAL DISCLAIMER	APPROVED		□ DISAPPROVED	
Date Filed : April 16, 2007	This patent is subject to a Terminal Disclaimer			
Approved/Disapproved by:				
Henry D. Jefferson				

U.S. Patent and Trademark Office

PTO/SB/26 (09-06)
Approved for use through 03/31/2007. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TERMINAL DISCLAIMER TO OBVIATE A DOUBLE DATENTING.

TERMINAL DISCLAIMER TO OBVIATE A DOUBLE PATENTING REJECTION OVER A "PRIOR" PATENT	Docket Number (Optional) 78258-329549
In re Application of: Gary L. Griffiths et al.	
Application No.: 10/066,782	
Filed: February 6, 2002	
For: Methods and compositions for increasing the target-specific toxicity of a chemotherapy drug	
except as provided below, the terminal part of the statutory term of any patent granted on the instant	prior patent is defined in 35 U.S.C. 154 owner hereby agrees that any patent so prior patent are commonly owned. This
In making the above disclaimer, the owner does not disclaim the terminal part of the term of any pater would extend to the expiration date of the full statutory term as defined in 35 U.S.C. 154 and 173 of the patent is presently shortened by any terminal disclaimer," in the event that said prior patent later: expires for failure to pay a maintenance fee; is held unenforceable; is found invalid by a court of competent jurisdiction; is statutorily disclaimed in whole or terminally disclaimed under 37 CFR 1.321; has all claims canceled by a reexamination certificate; is reissued; or is in any manner terminated prior to the expiration of its full statutory term as presently shortened to	prior patent, "as the term of said prior
Check either box 1 or 2 below, if appropriate.	
1. For submissions on behalf of a business/organization (e.g., corporation, partnership, university etc.), the undersigned is empowered to act on behalf of the business/organization.	, government agency,
I hereby declare that all statements made herein of my own knowledge are true and that a belief are believed to be true; and further that these statements were made with the knowledge that made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United statements may jeopardize the validity of the application or any patent issued thereon.	willful false statements and the like so
2. The undersigned is an attorney or agent of record. Reg. No. 42,023	
the transfer of the same of th	4/16/07
Signature	Date
Richard A. Nakashima	
Typed or printed name	
	303-447-7728 Telephone Number
Terminal disclaimer fee under 37 CFR 1.20(d) included.	•
WARNING: Information on this form may become public. Credit card inform be included on this form. Provide credit card information and authorization	ation should not on PTO-2038.
"Statement under 37 CFR 3.73(b) is required if terminal disclaimer is signed by the assignee (owner).	

This collection of Information is required by 37 CFR 1.321. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.